Treatment-free remission after imatinib discontinuation is possible in paediatric patients with chronic myeloid leukaemia

British Journal of Haematology

Volumn 168, Issue 2, 2015, Pages 305-308

  Giona, Fiorina ^a   Saglio, Giuseppe ^b   Moleti, Maria Luisa ^a   Piciocchi, Alfonso ^c   Rea, Massimiliano ^a   Nanni, Mauro ^a   Marzella, Deborah ^a   Testi, Anna Maria ^a   Mariani, Sabrina ^a   Laurino, Marica ^a   Diverio, Daniela ^a   Gottardi, Enrico ^b   Foà, Robin ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c GIMEMA Data Center   (Italy)

Author keywords

BCR ABL1; Childhood; Chronic myeloid leukaemia; Imatinib; Treatment free remission

Indexed keywords

ALPHA INTERFERON; IMATINIB; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADOLESCENT; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; LETTER; LEUKEMIA REMISSION; MALE; PRIORITY JOURNAL; SCHOOL CHILD; UNSPECIFIED SIDE EFFECT; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; REMISSION;

ADOLESCENT; BENZAMIDES; CHILD; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION;

EID: 84923804705     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13103     Document Type: Letter

References (10)

1. Bansal, D., Shava, U., Varma, N., Trehan, A. & Marwaha, R.K. (2012) Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatric Blood & Cancer, 59, 481-484.
2. Champagne, M.A., Fu, C.H., Chang, M., Chen, H., Gerbing, R.B., Alonzo, T.A., Cooley, L.D., Heerema, N.A., Oehler, V., Wood, C., French, M.E., Arceci, R.J., Smith, F.O. & Bernstein, M.L. (2011) Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group. Pediatric Blood & Cancer, 57, 56-62.
3. Cross, N.C., White, H.E., Müller, M.C., Saglio, G. & Hochhaus, A. (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia, 26, 2172-2175.
4. Giona, F., Putti, M.C., Santoro, N., Gottardi, E., Ladogana, S., Micalizzi, C., Iaria, G., Consarino, C., Burnelli, R., Rea, M., Nanni, M., Messina, C., Diverio, D., Biondi, A., Pession, A., Locatelli, F., Saglio, G. & Foà, R. (2010) Imatinib Mesylate induces high complete cytogenetic and major molecular response rates in children and adolescents with Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase. Haematologica (EHA Annual Meeting Abstract), 95, 346.
5. Giona, F., Mariani, S., Gnessi, L., Moleti, M.L., Rea, M., De Vellis, A., Marzella, D., Testi, A.M. & Foà, R. (2013) Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty. Haematologica, 98, 25-27.
6. Mahon, F.X., Réa, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F., Legros, L., Charbonnier, A., Guerci, A., Varet, B., Etienne, G., Reiffers, J. & Rousselot, P. (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. The Lancet Oncology, 11, 1029-1035.
7. Millot, F., Guilhot, J., Nelken, B., Leblanc, T., De Bont, E.S., Békassy, A.N., Gadner, H., Sufliarska, S., Stary, J., Gschaidmeier, H., Guilhot, F. & Suttorp, M. (2006) Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia, 20, 187-192.
8. Millot, F., Baruchel, A., Guilhot, J., Petit, A., Leblanc, T., Bertrand, Y., Mazingue, F., Lutz, P., Vérité, C., Berthou, C., Galambrun, C., Bernard, F., Yacouben, K., Bordigoni, P., Edan, C., Reguerre, Y., Couillault, G., Méchinaud, F., Cayuela, J.M. & Guilhot, F. (2011) Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. Journal of Clinical Oncology, 29, 2827-2832.
9. Ross, D.M., Branford, S., Seymour, J.F., Schwarer, A.P., Arthur, C., Yeung, D.T., Dang, P., Goyne, J.M., Slader, C., Filshie, R.J., Mills, A.K., Melo, J.V., White, D.L., Grigg, A.P. & Hughes, T.P. (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood, 122, 515-522.
10. Thielen, N., Van Der Holt, B., Cornelissen, J.J., Verhoef, G.E., Gussinklo, T., Biemond, B.J., Daenen, S.M., Deenik, W., Van Marwijk Kooy, R., Petersen, E., Smit, W.M., Valk, P.J., Ossenkoppele, G.J. & Janssen, J.J. (2013) Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). European Journal of Cancer, 49, 3242-3246.